WARRINGTON, Pa., June 24, 2008 (PRIME NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced today that Robert J. Capetola, Ph.D., President and Chief Executive Officer of Discovery Labs, will present an update on the Company's recent progress at the Jefferies 2nd Annual Healthcare Conference to be held in New York. The conference will be simultaneously webcast over the Internet.
Dr. Capetola is scheduled to present at 11:15 a.m. E.T. on Thursday, June 26, 2008. The presentation will be available through a live audio webcast at http://www.wsw.com/webcast/jeff26/dsco or Discovery Labs' web site, www.discoverylabs.com. A replay of the audio webcast will be available on both websites for thirty days.
About Discovery Labs
Discovery Laboratories, Inc. is a biotechnology company developing Surfactant Replacement Therapies (SRT) for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' technology produces a peptide-containing synthetic surfactant that is structurally similar to pulmonary surfactant. Discovery Labs believes that, with its proprietary technology, SRT has the potential, for the first time, to advance respiratory medicine and address a variety of respiratory diseases affecting neonatal, pediatric and adult patients.
SURFAXIN(r), the Company's lead product from its SRT pipeline, is the subject of an Approvable Letter from the FDA for the prevention of Respiratory Distress Syndrome in premature infants. SURFAXIN is also being developed for other neonatal and pediatric indications. AEROSURF, Discovery Labs' aerosolized SRT, is being developed to potentially obviate the need for intubation and conventional mechanical ventilation and holds the promise to significantly expand the use of surfactants in respiratory medicine. For more information, please visit our website at www.Discoverylabs.com.